Skip to main content
. Author manuscript; available in PMC: 2014 Apr 2.
Published in final edited form as: Sci Transl Med. 2013 Jun 5;5(188):188ra75. doi: 10.1126/scitranslmed.3006168

Fig. 6. Immune cell subsets after ETIMS treatment.

Fig. 6

(A to C) Percentage of (A) B cells (CD45+CD19+), monocytes (CD45+CD14+), T cells (CD45+CD3+CD56−), NK cells (CD45+CD3−CD56+), and NK T cells (CD45+CD3+CD56+); (B) CD4+ T cells (CD3+CD4+CD8−), including TH1 (CD4+IFN-γ+), TH17 (CD4+IL-17+), TH2 (CD4+IL-4+), Tregs (CD4+FoxP3+), and Tr1 (CD4+IL-10+); and (C) CD8+ T cells (CD3+CD4+CD8+), including regulatory CD8+ (CD8+CD57+ILT2+) and proinflammatory CD8+ (CD8+CD161high) measured by flow-cytometry in patients 6, 7, 8, and 10 before (month −1) and after (month 3) ETIMS treatment. Means ± SEM is shown. Dotted lines indicate the time point of study drug administration.